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The present study examines the molecular mechanisms by which a member of a novel series of pyrrolo-1,5-benzoxazepines, PBOX-21,
induces G1 arrest in 1321N1 cells. PBOX-21-induced G1 arrest is preceded by both a decrease in CDK2 kinase activity, which is critical for
the G1/S transition, and a downregulation in cyclin D3 protein expression levels, suggesting that these two events may be crucially involved
in the mediation of the cell cycle arrest. The decrease in CDK2 activity may be due to an observed decrease in CDK2 protein levels following
PBOX-21 treatment. Coinciding with the arrest is a reduction in the activity of CDK4, due to either the observed PBOX-21 induced
downregulation in CDK4 expression, or a reduction in complex formation between cyclin D3–CDK4 leading to a decrease in the levels of
active cyclin D3–CDK4 complexes with kinase activity. The level of CDK6 activity was also seen to be reduced following PBOX-21
treatment, also possibly due to a reduction in complex formation with cyclin D3. However, this reduction in CDK6 kinase activity was not
seen until after PBOX-21-induced G1 arrest has reached its maximum, and therefore may be viewed as a consequence of, and a method of
maintaining the PBOX-21-induced arrest, rather than a cause. Also in parallel with the G1 arrest elicited by PBOX-21 is an upregulation in
the universal CDK inhibitor, p21. Furthermore, the retinoblastoma protein (Rb), a substrate of CDK2 and CDK6, whose phosphorylation is
necessary for cell cycle progression, becomes hypophosphorylated. These results indicate that PBOX-21 exerts its growth inhibitory effects
through the modulation of the expression and activity of several key G1 regulatory proteins.
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We have previously shown that some members of a
series of novel pyrrolo-1, 5-benzoxazepines (PBOXs) elicit
antiproliferative effects upon tumour cells including human
1321N1 astrocytoma cells [1]. These PBOX compounds
were found to induce a specific accumulation of cells in the
G1 phase of the cell cycle, although the time of onset of the
G1 arrest remains unclear. Significantly, the antiproliferative
effects of these compounds were found to be entirely due to
this G1 arrest as the PBOX compounds were not cytotoxic
to the cells.
Cancer has always been attributed to an abnormal
proliferation of cells, and agents that interfere with cell0925-4439/$ - see front matter D 2003 Published by Elsevier B.V.
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peutics. The discovery of inhibitors of the cell cycle such
as paclitaxel [2] and olomucine [3] has led to rapid
advances in the investigation and design of a variety of
anti-mitotic compounds that are used clinically or have the
potential for development as antiproliferative agents. The
cytostatic effects of PBOX compounds in human tumour
cell lines indicated the potential of these compounds for
use as novel anticancer drugs and prompted us to examine
the direct mechanisms responsible for the initiation and/or
maintenance of the growth-arrested state. Because cell
growth and proliferation are ultimately regulated by a
highly conserved set of cell cycle regulatory proteins, a
productive approach to the study of the antiproliferative
mode of action of the PBOXs is to examine their
influence on the regulation of the cell cycle-regulating
machinery.
The eukaryotic cell cycle is regulated by the action of the
cyclin-dependent kinases (CDKs) and their activating sub-
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with either D- or E-type cyclins, and CDK4 and CDK6
associated with D-type cyclins, regulate G1 progression.
Progression from G1 to S requires inactivation of the
retinoblastoma protein (Rb) by phosphorylation and the
consequent release of a number of factors including the
E2F family of transcription factors. These transcription
factors then activate transcription of various genes that
promote cell cycle progression. Thus the phosphorylation
status of Rb is a critical determinant in the execution of the
progression of G1 to S.
In the present study, we systematically analysed the
changes that occurred in kinase activities, expression levels,
interactions and phosphorylation status of the cell cycle
regulatory molecules in human 1321N1 cells, in response to
treatment with a potent antiproliferative PBOX compound,
PBOX-21, and compared them to the timing of onset of the
growth arrest process.Fig. 1. Growth response of 1321N1 cells to PBOX-21. 1321N1 cells
(2.5 106) cells were seeded in 175 cm2 flasks and either left untreated or
treated with PBOX-21 (25 AM). Cell number was counted at the indicated
times using a hemocytometer. Results represent the meanF S.E.M. of three
separate experiments.2. Materials and methods
2.1. Cell culture
1321N1 cells were obtained from the European Col-
lection of Animal Cell Culture (Salisbury, UK) and were
grown in Dulbecco’s Modified Essential Medium supple-
mented with 10% (v/v) Foetal Calf Serum (FCS), 2 mM
L-glutamine and 100 Ag/ml gentamicin (complete medi-
um) all obtained from Sigma (Poole, Dorset, UK). The
pyrrolobenzoxazepine 7-[(diethylcarbamoyl)oxy]-6-p-toyl-
pyrrolo[2,1-d][1,5]benzoxazepine (PBOX-21) was syn-
thesised as described previously [5]. To ensure expo-
nential cell growth, 1321N1 cell cultures were set up
48 h prior to treatment with either vehicle (0.5% ethanol
(v/v)) or PBOX-21 (25 AM) for the indicated times. Cells
were harvested and processed for cell growth curve,
MTT assays, flow cytometric analysis, immunoprecipita-
tion, Western blotting and kinase assays as described
below.
2.2. Determination of cell growth curve
1321N1 cells (2.5 106) were seeded in 175 cm2 flasks
and following 48 h were treated with or without PBOX-21
(25 AM). Viable cell number was determined at the indicat-
ed times by counting the trypan blue-excluding cells using
hemocytometer.
2.3. MTT assay
Proliferation of 1321N1 cells in response to PBOX-21
was determined using the MTT assay as described previ-
ously [6]. Fifty microliters of 5 mg/ml MTT was added to
the culture medium of growing cells and incubated for 3 h at
37 jC. The medium was removed and 200 Al of DMSO wasadded to each well. The absorbance of the dissolved dye
was measured at 540 nm.
2.4. Flow cytometric cell cycle analysis
Flow cytometric analysis was performed as described
previously [1] using a Becton Dickinson FACSCalibur flow
cytometer. Analysis of data was performed using the com-
puter program Cell Quest.
2.5. Immunoprecipitation and kinase assays
Cell lysates for immunoprecipitation were prepared as
previously described [7]. Equal amounts of protein (200–
500 Ag) were incubated with the appropriate antibody for 3
h at 4 jC. Antibody complexes were recovered on protein
A-Sepharose beads (Sigma). The in vitro kinase assays were
performed as previously described [7] in the presence of
either 10 Ag of histone H1 (Sigma) or GST-Rb fusion
protein (Santa Cruz) and 5 ACi of [g32P]ATP (Amersham
International) per reaction. Samples were then analysed on
SDS-PAGE followed by autoradiography.
2.6. Western blot analysis
Preparation of cell lysates and Western blot analysis
was performed as previously described [8]. A 10% SDS-
PAGE gel was used for detection of cyclin E, whilst a 12%
SDS-PAGE gel was used for detection of cyclins D2 and
D3, CDK2, CDK4, CDK6, p21 and h-actin. A 5–20%
gradient gel was employed for detection of Rb phosphor-
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D3, p21 and Rb were obtained from BD-Pharmingen.
Antibodies for cyclin D1 and E were obtained from
Oncogene, the antibody for cyclin D2 was obtained from
Calbiochem and the h-Actin antibody was obtained from
Sigma.3. Results
3.1. PBOX-21-treated 1321N1 cells display decreased
proliferation and an accumulation in the G1 phase
To assess the inhibitory effect of PBOX-21 on the
growth of 1321N1 cells, we determined their growth rateFig. 2. Changes in cell cycle phase distribution following PBOX-21 treatment.
incubated at 37 jC for 48 h until the cells were in the exponential phase of growth
(25 AM) for the indicated times and analysed by flow cytometry. The cell cyc
meanF S.E.M. of four separate experiments. Statistical analysis was carried out
vehicle treatment; Student’s t-test.in the absence and presence of both vehicle (0.5% ethanol
(v/v)) and PBOX-21 (25 AM) (Fig. 1). Proliferation of
exponentially growing 1321N1 cells was inhibited follow-
ing treatment with PBOX-21 with an inhibitory effect seen
after 24 h, and the cell number did not increase signifi-
cantly after 48 h. This indicates that the action of PBOX-
21 is exerted rapidly. The vehicle itself inhibited cell
proliferation slightly over time (Fig. 1). A lower concen-
tration of ethanol could not be used due to solubility
problems with the PBOX compounds. Thus, vehicle con-
trols were included in all subsequent experiments involved
in elucidating the mechanism of the growth inhibition
initiated by PBOX-21.
To characterise the antiproliferative action of PBOX-21,
an analysis of the distribution of cells within the various1321N1 (2.5 106) cells were seeded down in 175 cm2 flasks and were
. The cells were then treated with vehicle (0.5% (v/v) ethanol) or PBOX-21
le phases sub-G1, G1, S and G2/M are indicated. Results represent the
using the Instat computer program. *P < 0.05, **P < 0.01 with respect to
Fig. 4. PBOX-21-induced cell cycle arrest is reversible. 1321N1 (3 105)
cells were seeded down in 25 cm2 flasks and incubated for 48 h until the
cells were in the exponential phase of growth. The cells were then treated
with either vehicle (0.5% (v/v) EtOH) or PBOX-21 (25 AM) and left for 24
h. The cells from vehicle and PBOX-21-treated flasks were harvested and
analysed by flow cytometry. The medium in the remaining flasks was
carefully removed and the cells washed in fresh medium. Another 5 ml of
fresh complete medium in the absence of PBOX-21 was added to the flasks
and the cells were incubated for a further 24 h. The cells were harvested and
prepared and analysed by flow cytometry. The results represent the
meanF S.E.M. of three separate experiments. Statistical analysis was
carried out using the Instat computer program. *P< 0.05, **< 0.01 with
respect to vehicle treatment; Student’s t-test.
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as a function of time following PBOX-21 treatment. No
change in cell cycle distribution was apparent during the
first 8 h following exposure to PBOX-21 (Fig. 2). A
significant increase in the percentage of cells in the G1
phase (Fig. 2B) and concomitant reduction in both S (Fig.
2C) and G2/M (Fig. 2D) was noticeable between 12 and
16 h relative to vehicle-treated cells, with a maximum
induction of G1 arrest being observed at 20 h. At 48 h,
although a significant G1 arrest was still noticeable in
response to PBOX-21 treatment, the vehicle itself (0.5%
ethanol (v/v)) also appeared to elicit a small effect, relative
to untreated cells, indicating that this arrest is not due to a
cell density effect. This is in agreement with the growth
curve data (Fig. 1). As can be seen from Fig. 2A, the
fraction of cells with a pre-G1 DNA-content (apoptotic/
necrotic cells) remained unchanged after treatment with
PBOX-21.
To determine if the effect of PBOX-21 on 1321N1 cell
cycle progression correlated with cell growth, MTT assays
were performed. Fig. 3 shows that PBOX-21 dose-depen-
dently inhibited 1321N1 cell proliferation which paralleled
the accumulation of cells in the G1 phase of the cell
cycle. Taken together, these results indicate that PBOX-21
inhibits cell growth by causing the arrest of 1321N1 cells
in G1.Fig. 3. Dose-dependent PBOX-21 inhibition of cell proliferation of 1321N1
cells parallels the cell cycle inhibition. For the MTT assay 1321N1 cells
(0.5 105) were seeded in each well of a 96-well plate in 200 Al medium.
For flow cytometric analysis, 1321N1 cells (2.5 106) were seeded in 175
cm2 flasks. The cells were left for 48 h, until they were in the exponential
phase of growth, after which they were treated with a final concentration of
1, 10, 25 and 50 AM of PBOX-21 and were incubated for a further 48 h.
The cell proliferation and cell cycle arrest is expressed as a percentage of
the vehicle (0.5% (v/v) EtOH) and was determined by performing an MTT
assay and flow cytometry analysis respectively, as described. The results
represent the meanF S.E.M. of three separate experiments.3.2. PBOX-21-induced cell cycle arrest is reversible
1321N1 cells were treated with PBOX-21 for 24 h after
which time the medium was removed and replaced by drug-
free medium. The cells were incubated for a further 24 h and
were harvested, prepared and analysed using flow cytometry
(Fig. 4). The 24 h treatment with PBOX-21 resulted in an
increase of 16% of the cells in G1 relative to the vehicle
control. Following removal of PBOX-21 and incubation in
the drug-free medium for a further 24 h, this G1 arrest was
seen to have been reversed as the percentage of cells within
the G1 phase was comparable between the vehicle and
treated samples. It would appear that incubation of the cells
in drug-free medium for 24 h was sufficient for transition
from the G1 block and allowed a return to a normal
distribution of cells within the various phases of the cell
cycle. This reversal of the G1 arrest indicates a specificity of
action of PBOX-21 and confirms its lack of toxicity to the
cells.
3.3. PBOX-21 causes a reduction in CDK2, CDK4 and
CDK6 kinase activity
Since CDKs regulate cell cycle progression, we next
investigated whether the PBOX-21-induced blockage at the
G1 phase of the cell cycle was associated with changes in
the activity of various CDKs responsible for mediating
G1–S progression, namely CDK2, 4 and 6. PBOX-21
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activity of CDK2 with a reduction of approximately 50% in
activity at 20 h (Fig. 5A). The reduction was clearlyFig. 5. PBOX-21 causes a time-dependent downregulation in CDK2, CDK4 an
following treatment with PBOX-21 for the indicated times. The protein was immun
activity was determined by phosphorylation of Histone H1 or Rb, respectively. Fo
Image software with 0 h set to 100%. The results shown are the meanF S.E.M.apparent at 8 h, which is before any changes in cell cycle
distribution could be detected, suggesting that this was a
cause of the G1 arrest. PBOX-21 treatment also caused ad CDK6 kinase activity. Whole cell extracts were prepared as described
oprecipitated with either CDK2, CDK4 or CDK6 antibodies and the kinase
r the graph, densitometry was performed on the resultant bands using Scion
of three separate experiments.
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5B and C). CDK4 activity declines later than that of CDK2,
with a reduction seen at 12 h, which coincides with the
onset of arrest, whilst a reduction in CDK6 activity does
not become apparent until 20 h, which is after the initial
observation of G1 arrest.
3.4. PBOX-21 causes an early downregulation in the
protein expression of CDK2, CDK4 and cyclin D3
We next examined whether changes in CDK kinase
activities are attributable to changes in the protein levels
of CDKs and of their cyclins. PBOX-21 treatment
resulted in a decrease in protein expression of CDK2
and CDK4 (Fig. 6A and B), beginning at 8 h and
maintained up to 48 h, indicating that the changes in
CDK2 and CDK4 activity may be due to changes in theirFig. 6. The effect of PBOX-21 on the expression levels of the CDKs. Cell lysates
PBOX-21 for the indicated times. Protein (70 Ag) was resolved using SDS-PAGE
CDK4 (B) or anti-CDK6 (C) antibodies. The blots were stripped and re-probed wit
separate experiments.protein expression levels. The amount of protein precip-
itated by the CDK2 and CDK4 antibodies also began to
decline with PBOX-21 treatment, in agreement with the
observed reduction in their expression levels. PBOX-21
treatment up to 48 h did not change the expression level
of CDK6 (Fig. 6C) suggesting that the observed reduction
in CDK6 kinase activity is not a result of a decrease in
its protein level.
The effect of PBOX-21 on the various G1 cyclins was
next analysed. PBOX-21 had no effect on the expression
level of cyclin E up to 48 h (Fig. 7A), suggesting that
this cyclin is not involved in the PBOX-21-mediated
arrest. As cyclin D1 was not expressed in 1321N1 cells
(unpublished data), we next examined the effect of
PBOX-21 on the levels of cyclin D2 and D3. It was
found that PBOX-21 treatment led to a downregulation in
the expression levels of cyclin D2 (Fig. 7B), but not untilwere prepared as described following treatment with either vehicle (V) or
, transferred onto PVDF membrane and probed with anti-CDK2 (A), anti-
h anti-h-actin antibody. The results shown are representative of at least three
Fig. 7. The effect of PBOX-21 on the expression levels of the G1 cyclins. Cell lysates were prepared as described following treatment with either vehicle (V) or
PBOX-21 for the indicated times. Protein (70 Ag) was resolved using SDS-PAGE, transferred onto PVDF membrane and probed with anti-cyclin E (A), anti-
cyclin D2 (B) or anti-cyclin D3 (C) antibodies. The blots were stripped and re-probed with anti-h-actin antibody. The results shown are representative of at least
three separate experiments.
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G1 arrest. Further analysis of expression of G1 cyclins
showed that the expression level of cyclin D3 was
reduced significantly after treatment with PBOX-21
(Fig. 7C). This downregulation in cyclin D3 levels was
first observed after 8 h of treatment which is prior to the
onset of G1 arrest, and around the time of the observed
reduction in CDK4 kinase activity. The PBOX-21 in-
duced decrease of cyclin D3 was maintained up to 16 h of
treatment. It should also be noted that after 16 h of
treatment, the levels of cyclin D3 within the untreated
1321N1 cells also began to decline, with no cyclin D3
expression visible at 48 h. This may be due to a
depletion within the culture medium of necessary growth
factors. The expression of the D-type cyclins is under the
control of mitogenic stimuli and once these begin to
diminish the cyclin may undergo ubiquitin-mediated
proteolysis [9].
The PBOX-21-induced early downregulation in cyclin
D3 may suggest that it is involved in the mechanism bywhich G1 arrest is initiated. Cyclin D3 is considered to
typically associate with either CDK4 and/or CDK6. It was
found that at 20 h of PBOX-21 treatment, when both CDK4
and CDK6 kinase activities are seen to be reduced, there
was a decrease in the complex formation between both
kinases and cyclin D3 (Fig. 8A and B).
3.5. PBOX-21 causes an upregulation in the protein
expression of p21
To further assess how PBOX-21 is mediating its anti-
proliferative effect, the expression levels of the CDK
inhibitors p16, p21 and p27 were analysed. There were no
detectable expression levels of p16 found within the
1321N1 cells and PBOX-21 treatment had no effect upon
the expression level of p27 (unpublished data). PBOX-21
did cause a transient upregulation in p21, with an initial
induction in expression seen after 16 h of treatment (Fig. 9)
after which time the expression declined up to 48 h of
PBOX-21 treatment.
Fig. 8. PBOX-21 causes a reduction in cyclin D3–CDK4 and cyclin D3–CDK6 complex formation. Cell lysates were prepared as described with either vehicle
or PBOX-21 for 20 h. The protein (200–500 Ag) was incubated with anti-CDK4 and anti-CDK6 antibodies and then incubated with Protein A beads. The
immunoprecipitated protein was resolved using SDS-PAGE, transferred to a PVDF membrane and probed with either anti-cyclin D3 antibody, anti-CDK4 or
anti-CDK6 antibodies. The results shown are representative of at least two separate experiments.
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of Rb
It has been shown that treatment with PBOX-21 resulted
in a sequential reduction in the kinase activities of CDK2,
CDK4 and CDK6. As the phosphorylation of Rb is medi-
ated by the cyclin–CDK complexes, it was necessary to
determine whether Rb became hypophosphorylated follow-
ing PBOX-21 treatment. The reduction in mobility of Rb on
SDS-PAGE and Western blot analysis is a widely accepted
indicator of Rb phosphorylation. In vehicle-treated cells, Rb
was found in both hyper- and hypophosphorylated forms
which migrated as two bands in the molecular mass range of
115–120 kDa (Fig. 10). PBOX-21 treatment caused aFig. 9. PBOX-21 causes an upregulation in the expression of p21. Cell lysates w
times. Protein (70 Ag) was resolved using SDS-PAGE, transferred onto PVDF and
anti-h-actin antibody. The results shown are representative of at least three separdisappearance of the slow migrating hyperphosphorylated
form of Rb.4. Discussion
This study demonstrates the potent growth inhibitory
effects of a representative PBOX compound, PBOX-21
upon the human 1321N1 astrocytoma cell line. The growth
inhibitory effects induced by PBOX-21, are mediated
through the induction of cell cycle arrest in the G1 phase,
and are not associated with cytotoxic effects. The induction
of G1 arrest is at the expense of cells in both S and G2/M
with cells being drawn equally from both phases into G1.ere prepared as described with either vehicle or PBOX-21 for the indicated
probed with anti-p21 antibody. The blots were stripped and re-probed with
ate experiments.
Fig. 10. PBOX-21 reduces the phosphorylation of Rb. Cell lysates were prepared as described with PBOX-21 for the indicated times. The protein (70 Ag) was
resolved using a gradient SDS-PAGE gel, transferred onto PVDF and probed with anti-Rb antibody. The blot was stripped and re-probed with anti-h-actin
antibody. The results shown are representative of at least two separate experiments.
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PBOX-21 mediates its antiproliferative action upon the
1321N1 cell line, a complete analysis of the cell cycle
events in these cells both prior to and consequent of the
initial observed G1 arrest at 12 h was performed. Thus, it
is possible to distinguish between induced changes in cell
cycle regulating molecules, which are possibly responsible
for the growth arrest, from those that are as a result of the
cell cycle arrest itself. In so doing, it was found that the
activities of CDK2, CDK4 and CDK6 were downregulated
sequentially. CDK2 kinase activity is the first to be
affected with a decrease seen as early as 8 h with CDK4
and CDK6 kinase activities reduced following 12 and 20
h of treatment with PBOX-21, respectively. These results
would suggest that the reduction in CDK2 and CDK4
activity is a mechanism of breaking the cell cycle during
the early phase of PBOX-21 treatment as CDK2 and
CDK4 activities are both respectively reduced both prior
to and coincident with any changes in cell cycle distribu-
tion. The reduction of CDK6 activity, on the other hand,
would appear to be a consequence of, and a method of
maintaining the PBOX-21-induced arrest, rather than a
cause.
In order to address the mechanism by which the
reduction in kinase activity of these CDKs occur, the
expression of the CDKs themselves and the various G1
cyclins and CDK inhibitors was analysed. It was found
that PBOX-21 caused a reduction in protein expression of
CDK2 and CDK4 in parallel with, and therefore explaining
at least in part, their observed decrease in kinase activity.
On the other hand, the expression levels of CDK6
remained unaffected by PBOX-21 treatment indicating an
alternative mechanism by which this kinase’s activity is
being modified.
Western blot analysis of the cyclins revealed that
PBOX-21 had no effect upon the expression level of
cyclin E. As cyclin E is known to complex with CDK2
late in the G1 phase, this indicates that the inhibition ofCDK2 occurs independent of its association with cyclin
E. Cyclin D1 was not found to be expressed within the
1321N1 cells, whilst cyclin D2 expression was seen to be
downregulated following 24 h of PBOX-21 treatment,
again indicating this to be a secondary response to the
cessation of cell cycle progression. In contrast, progres-
sion of the expression level of cyclin D3 is reduced
significantly, with downregulation occurring after 8 h of
treatment, preceding the arrest and suggesting a role in
the mechanism by which G1 arrest is induced. The
downregulation of cyclin D3 may be responsible in part
for the reduction in the kinase activities of CDK4 and
CDK6, due to a reduction in complex formation between
these kinases and cyclin D3 leading to a decrease in the
levels of active cyclin D3–CDK4 and cyclin D3–CDK6
complexes with kinase activity. In order to confirm this
theory, the association between cyclin D3 and CDK4 and
CDK6 was analysed and revealed a reduction in complex
formation between both these kinases and cyclin D3.
Therefore, cyclin D3 downregulation may be responsible
for the maintenance of PBOX-21-mediated G1 arrest via
modulation of CDK4 and CDK6 kinase activity. At
present, we do not know whether the reduction in cyclin
D3 expression occurs through active transcriptional re-
pression or by a post-translational mechanism affecting
protein stability of cyclin D3. It would also be of interest
in the future to determine whether enforced expression of
cyclin D3 could abrogate PBOX-21-induced G1 arrest.
Another method by which CDK activity and thus cell
cycle progression is modulated is via the expression of the
CDK inhibitors. This study looked at the expression of p16,
p27 and p21. It was found that p16 was not expressed within
the 1321N1 cells and that PBOX-21 did not result in a
change in expression in p27 nor in a redistribution of its
association with the various CDKs (unpublished data).
PBOX-21 treatment did however result in a transient upre-
gulation in the expression of p21, with an initial and
maximal induction in expression seen after 16 h. After this
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48 h. Again, as this effect is seen following the G1 arrest
onset, p21 induction cannot be viewed as a causative factor
in the arrest observed, but instead may play a role in its
maintenance.
It is well-documented that a major subcellular target of
the cyclin–CDK complexes is the Rb ensuring progression
through the cell cycle by maintaining Rb in a hyperphos-
phorylated state. Growth inhibition is thus often associated
with suppression of Rb phosphorylation retaining Rb in an
unphosphorylated, growth inhibitory state. After treatment
with PBOX-21, a clear mobility shift was observed in the
Rb protein from the hyperphosphorylated to the hypophos-
phorylated form. This result is consistent with the reduced
CDK2, CDK4 and CDK6 activity in PBOX-21-treated cells
as Rb is a substrate of these kinases.
In conclusion, our findings demonstrate that PBOX-21
inhibits the growth of 1321N1 cells by arresting them at
the G1 phase of the cell cycle, and the arrest is preceded
by a rapid decrease in CDK2 kinase activity and cyclin
D3 expression. The arrest is concomitant with a decrease
in CDK4 kinase activity, indicating that these events are
likely to be part of the mechanism responsible for initi-
ating the G1 arrest. The inhibition of the activity of both
CDK2 and CDK4 is at least in part due to their early
downregulation in protein expression. The decrease in
CDK4 activity might also be due to the decreased
complex association of CDK4 with cyclin D3. The later
reduction in CDK6 kinase activity and its decreased
association with cyclin D3, as well as the upregulation
of p21 and downregulation of cyclin D2 may be involved
in maintaining the arrest. Furthermore, we found that Rb
becomes hypophosphorylated in response to PBOX-21
treatment. These results indicate that PBOX-21 exerts its
growth inhibitory effects through the modulation of the
expression and/or activity of several key G1 regulatory
proteins. It will be important in our future studies to
define the upstream signal transduction pathway mediating
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